Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MP0250 plus BOR+DEX · 1 trial · 1 indication
Defined as the number of participants achieving a complete response (CR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 1.
Defined as the number of participants achieving a confirmed, stringent complete response (sCR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 2.
| Arm | Type | Description |
|---|---|---|
| Single arm Study MP0250 plus BOR + DEX | EXPERIMENTAL | Single arm study of MP0250 plus bortezomib + dexamethasone |
| Name | Type | Description |
|---|---|---|
| MP0250 plus BOR+DEX | BIOLOGICAL | 6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label. Number of Cycles: until progression or unacceptable toxicity develops. |
Inclusion Criteria: 1. Patients with MM who have received: * Part 1 ≥2 lines of therapy (including bortezomib and an IMiD) and have shown no response (i.e. stable disease) to, have progressed on the most recent treatment or have progressed within 60 days of the most recent therapy * Part 2 ≥...
MP0250 is an investigational small molecule being studied for the treatment of cancer, including multiple myeloma in relapse. It is currently in clinical development and has not been approved by regulatory authorities.
MP0250 is being developed by Molecular Partners AG, a biopharmaceutical company traded on the NASDAQ under the ticker symbol MOLN.
MP0250 is in Phase 1 of clinical development. It is an investigational drug and has not yet received regulatory approval for any indication.
MP0250 has been studied in two clinical trials. The first, NCT02194426, was a first-in-human study in cancer patients. The second, NCT03136653, was a Phase 2 trial of MP0250 plus bortezomib and dexamethasone in patients with multiple myeloma in relapse.
MP0250 is the sole name used for this investigational drug in the clinical trial records. No alternative names have been associated with it in the available data.